Stockscreener 앱 받기
6.27
2.18%
-0.14
시간 외 거래:
6.27
전일 마감가:
$6.41
열려 있는:
$6.41
하루 거래량:
3.64M
Relative Volume:
0.72
시가총액:
$1.09B
수익:
$847.25M
순이익/손실:
$-284.86M
주가수익비율:
-2.738
EPS:
-2.29
순현금흐름:
$-112.35M
1주 성능:
-6.49%
1개월 성능:
+0.48%
6개월 성능:
-33.58%
1년 성능:
+27.18%
1일 변동 폭
$6.26
$6.61
1주일 범위
$6.24
$6.7579
52주 변동 폭
$4.43
$23.86
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
NVAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
6.27 | 1.09B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 개시 | BTIG Research | Buy |
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
Japan Enhances Non-mRNA COVID-19 Vaccine Availability - Vax-Before-Travel
Novavax reports revised terms for Takeda agreement for Nuvaxovid in Japan - MSN
Novavax (NVAX) Strengthens Partnership with Takeda for Nuvaxovid in Japan - GuruFocus
Novavax Updates Financial Terms With Takeda for Covid-19 Vaccine Agreement in Japan - marketscreener.com
B. Riley Cuts Price Target on Novavax to $18 From $22, Keeps Buy Rating - marketscreener.com
Novavax revises Takeda deal for Japan vaccine sales - Investing.com
Novavax revises Takeda deal for Japan vaccine sales By Investing.com - Investing.com India
Novavax Announces Improved Financial Terms In Its Agreement With Takeda For Nuvaxovid In Japan - Nasdaq
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan | NVAX Stock News - GuruFocus
Novavax (NVAX) Updates Agreement with Takeda for Nuvaxovid in Japan | NVAX Stock News - GuruFocus
Novavax Secures Enhanced Takeda Deal for COVID Vaccine in Japan Market | NVAX Stock News - Stock Titan
Novavax to Report First-Quarter Earnings: Is a Beat in Store? - Nasdaq
FDA to Mandate Placebo-Controlled Trials for New Vaccines - MSN
Novavax (NVAX) Flat As Market Gains: What You Should Know - Yahoo Finance
Novavax (NVAX) Sees Increased Bearish Options Activity | NVAX Stock News - GuruFocus
RFK Jr.’s New Vaccine Scrutiny Is Alarming - Bloomberg.com
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 - Longview News-Journal
FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots - Bluefield Daily Telegraph
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 | NVAX Stock News - GuruFocus
Novavax Q1 2025 Earnings Call Coming Next Week: Key Details for Investors - Stock Titan
FDA to Require Placebo-Controlled Trials for Vaccine Approvals - Bloomberg.com
Novavax expands board, appoints Charles W. Newton as director - Investing.com Australia
Novavax appoints Charles Newton to board of directors - Investing.com
Novavax expands board, appoints Charles W. Newton as director By Investing.com - Investing.com Nigeria
Novavax appoints Charles Newton to board of directors By Investing.com - Investing.com India
FDA Scrutiny of Novavax COVID Shot Sparks Uncertainty About Other Vaccines - MedPage Today
Novavax (NVAX) Welcomes Charles Newton to Board of Directors | N - GuruFocus
Novavax Appoints Charles Newton to Board of Directors | NVAX Sto - GuruFocus
Novavax Appoints Charles Newton To Board Of Directors - marketscreener.com
Novavax Appoints Charles Newton to Board of Directors - Seeking Alpha
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline - Benzinga
FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty - TelegraphHerald.com
NVAX Engages with Shah Capital for Strategic Growth Initiatives - GuruFocus
FDA Scrutiny Of Novavax COVID-19 Vaccine Sparks Uncertainty About Other Shots - Barchart.com
Novavax told by FDA to conduct additional study for COVID vaccinereport - MSN
Does the Novavax delay augur a COVID vaccine policy change? - pharmaphorum
Nvidia & chip stocks falling, Novavax vaccine, Zscaler upgrade - Yahoo Finance
Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot. - Barron's
Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny - Endpoints News
Novavax says vaccine application still ‘approvable,’ despite FDA delay - BioPharma Dive
Novavax Stock Is Up Again on More Covid Shot News and Speculation - Barron's
FDA's Continued Delay on Novavax (NVAX) Vaccine Approval Raises Concerns | NVAX Stock News - GuruFocus
Novavax’s COVID-19 Vaccine Awaits FDA Decision Amid Request For More Data - The Seattle Medium
Lobbying Update: $170,000 of NOVAVAX INC lobbying was just disclosed - Nasdaq
Novavax Falls on Report That FDA Wants New Covid Vaccine Trial - MSN
Novavax : Latest update on U.S. FDA BLA for Novavax's COVID-19 Vaccine - marketscreener.com
Novavax: Grandiose Ambitions, Smart Strategy, But FDA Decision Adds To Challenges (NVAX) - Seeking Alpha
‘Regulatory Headwinds Set to Bite,’ Says Top Analyst on Novavax Stock (NVAX) - TipRanks
U.S. health officials inject new uncertainty into approval process for Covid boosters - statnews.com
Trending tickers: latest investor updates on Deliveroo, Reliance, Toyota, Novavax and M&S - Yahoo
Novavax Tops Weekly Retail Buzz Spike Amid FDA Trial Drama, COVID-19 Vaccine Approval Hopes - MSN
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):